Medindia

X

Transgene Biotek Gets US Patent for Developing Novel Drug to Treat Liver Cancer

by Bidita Debnath on  July 7, 2015 at 5:30 PM Drug News   - G J E 4
Biotechnology firm Transgene Biotek has received patent in the US for its novel drug to be developed for treatment of Hepato-cellular cancer (HCC) the most common liver cancer.
Transgene Biotek Gets US Patent for Developing Novel Drug to Treat Liver Cancer
Transgene Biotek Gets US Patent for Developing Novel Drug to Treat Liver Cancer
Advertisement

"This granting of a USA patent is a significant step in moving ahead with the development of this novel drug," Transgene Biotek said in a filing to the BSE (Bombay Stock Exchange).

Advertisement
The company's novel molecule miRNA 101 for therapy against liver cancer has been allowed for issuance of a USA patent after the prosecution on merits have been closed, it added.

HCC is the most common primary liver cancer, accounting to roughly 90% of this class of malignancy, with poor prognosis due to its ability to rapidly spread, Transgene Biotek said.

The company's current product portfolio covers segments such as oncology, auto-immunity, drug delivery and bio-generics.

Shares of Transgene Biotek closed 4.90% up at Rs 2.57 per scrip on the BSE.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All